- Home
- PLX vs JYNT Comparison
PLX vs JYNT Comparison
Compare PLX & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- JYNT
- Stock Information
- Founded
- PLX 1993
- JYNT 2010
- Country
- PLX United States
- JYNT United States
- Employees
- PLX N/A
- JYNT N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- JYNT Multi-Sector Companies
- Sector
- PLX Health Care
- JYNT Miscellaneous
- Exchange
- PLX Nasdaq
- JYNT Nasdaq
- Market Cap
- PLX 164.2M
- JYNT 149.5M
- IPO Year
- PLX 1998
- JYNT 2014
- Fundamental
- Price
- PLX $2.60
- JYNT $8.83
- Analyst Decision
- PLX Strong Buy
- JYNT Strong Buy
- Analyst Count
- PLX 1
- JYNT 3
- Target Price
- PLX $15.00
- JYNT $16.33
- AVG Volume (30 Days)
- PLX 792.6K
- JYNT 90.2K
- Earning Date
- PLX 11-13-2025
- JYNT 11-06-2025
- Dividend Yield
- PLX N/A
- JYNT N/A
- EPS Growth
- PLX N/A
- JYNT N/A
- EPS
- PLX 0.08
- JYNT N/A
- Revenue
- PLX $61,948,000.00
- JYNT $53,449,713.00
- Revenue This Year
- PLX $14.53
- JYNT $7.70
- Revenue Next Year
- PLX $75.77
- JYNT $10.24
- P/E Ratio
- PLX $33.57
- JYNT N/A
- Revenue Growth
- PLX 62.79
- JYNT 277.36
- 52 Week Low
- PLX $0.99
- JYNT $8.77
- 52 Week High
- PLX $3.10
- JYNT $13.47
- Technical
- Relative Strength Index (RSI)
- PLX 82.14
- JYNT 23.17
- Support Level
- PLX $1.52
- JYNT $9.06
- Resistance Level
- PLX $2.12
- JYNT $9.93
- Average True Range (ATR)
- PLX 0.12
- JYNT 0.32
- MACD
- PLX 0.05
- JYNT -0.09
- Stochastic Oscillator
- PLX 96.79
- JYNT 5.36
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.